The challenge of risk reduction therapy for cardiovascular disease.
Patients with cardiovascular disease can derive significant benefit from the implementation of risk reduction therapies. Until recently, management of patients with coronary heart disease has centered on the use of angioplasty, bypass surgery and medical therapy for severe fixed obstructions. Several large randomized clinical trials now demonstrate the importance of medical risk reduction therapies in these patients. A consensus panel of the American Heart Association recommends that health care providers use a group of risk reduction therapies, which can significantly extend overall survival, improve quality of life, decrease the need for interventional procedures such as angioplasty and bypass grafting, and reduce the incidence of subsequent myocardial infarction. Since a minority of patients with cardiovascular disease now benefit from these strategies, changes in our health care delivery systems are recommended. Risk reduction case management by nursing staff can assist physicians and improve implementation of and patient adherence to these therapies. Programs are being discussed to develop support by third-party insurers for risk reduction therapies. Application of these therapies should be a routine part of care for patients with cardiovascular disease.
Smith
S C
SC
Division of Cardiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill 27599-7075, USA.
D000572:American Heart Association; D002317:Cardiovascular Agents / Q000627:therapeutic use; D019090:Case Management; D003327:Coronary Disease / Q000209:etiology* / Q000517:prevention & control*; D015444:Exercise; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000628:therapy; D006973:Hypertension / Q000150:complications / Q000628:therapy; D009203:Myocardial Infarction / Q000517:prevention & control; D009726:Nurses; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D016540:Smoking Cessation; D015996:Survival Rate; D014481:United States; D015431:Weight Loss
D002317:Cardiovascular Agents